Abruzzese E, Bocchia M, Trawinska MM, Raspadori D, Bondanini F, Sicuranza A, Pacelli P, Re F, Cavalleri A, Farina M et al (2023) Minimal residual disease detection at RNA and leukemic stem cell (LSC) levels: comparison of RT-qPCR, d-PCR and CD26+ stem cell measurements in chronic myeloid leukemia (CML) patients in deep molecular response (DMR). Cancers 15:4112. https://doi.org/10.3390/cancers15164112

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adnan-Awad S, Kankainen M, Mustjoki S (2021) Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. Leuk Lymphoma 62:2064–2078. https://doi.org/10.1080/10428194.2021.1894652

Article  CAS  PubMed  Google Scholar 

Adytia GJ, Sutanto H, Pratiwi L, Fetarayani D (2025) Advances in synthetic immunology for targeted treatment of systemic autoimmune diseases: opportunities, challenges, and future directions. Immuno 5:6. https://doi.org/10.3390/immuno5010006

Article  Google Scholar 

Ahmed S (2024) Neoantigen-based cancer vaccines: current innovations, challenges, and future directions in personalized immunotherapy. CI Connect 1:1–10. https://doi.org/10.69709/CIConnect.2024.194763

Article  Google Scholar 

Akter S (2024) AI-driven precision medicine: transforming personalized cancer treatment. JAPMI 2:10–21. https://doi.org/10.60087/vol2iisue1.p21

Article  Google Scholar 

Alikian M, Ellery P, Forbes M, Gerrard G, Kasperaviciute D, Sosinsky A, Mueller M, Whale AS, Milojkovic D, Apperley J et al (2016) Next-generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients. J Mol Diagn 18:176–189. https://doi.org/10.1016/j.jmoldx.2015.09.005

Article  CAS  PubMed  Google Scholar 

Alves R, Gonçalves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, Sarmento Ribeiro AB (2021) Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance. Cancers 13:4820. https://doi.org/10.3390/cancers13194820

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ament IH, DeBruyne N, Wang F, Lin L (2024) Long-read RNA sequencing: a transformative technology for exploring transcriptome complexity in human diseases. Mol Ther. https://doi.org/10.1016/j.ymthe.2024.11.025

Article  PubMed  PubMed Central  Google Scholar 

Amiri M, Moaveni AK, Majidi Zolbin M, Shademan B, Nourazarian A (2024) Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR/Cas9. Front Immunol 15:1462697. https://doi.org/10.3389/fimmu.2024.1462697

Article  CAS  PubMed  PubMed Central  Google Scholar 

Babar H, Malik HS, Umar M, Tasleem Z, Tahir N (2024) Prognostic and predictive implications of sokal scoring system in newly diagnosed chronic myeloid leukemia patients. Ann Pak Inst Med Sci 20:126–130. https://doi.org/10.48036/apims.v20i2.842

Article  Google Scholar 

Bahashwan SM (2024) Chronic myeloid leukemia with a rare philadelphia chromosome variant involving chromosome 16. Am J Case Rep 25:e944641. https://doi.org/10.12659/AJCR.944641

Article  PubMed  PubMed Central  Google Scholar 

Baraa L, Nader S, Ines O, Boufrikha W, Laatiri A (2023) PB1964: comparison of clinico-hematological parameters and molecular and cytogenetic response of two BCR-ABL fusion transcripts in chronic myeloid leukemia treated with imatinib. HemaSphere 7:e0192008. https://doi.org/10.1097/01.HS9.0000974672.01920.08

Article  PubMed Central  Google Scholar 

Bavaro L, Martelli M, Cavo M, Soverini S (2019) Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. IJMS 20:6141. https://doi.org/10.3390/ijms20246141

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bayle A, Marino P, Baffert S, Margier J, Bonastre J (2024) Coût des technologies de séquençage haut débit (NGS): revue de la littérature et enseignements. Bulletin du Cancer 111:190–198. https://doi.org/10.1016/j.bulcan.2023.08.013

Article  PubMed  Google Scholar 

Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, Sasaki K, Issa GC (2022) Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 12:144. https://doi.org/10.1038/s41408-022-00742-1

Article  PubMed  PubMed Central  Google Scholar 

Boers SA, Jansen R, Hays JP (2019) Understanding and overcoming the pitfalls and biases of next-generation sequencing (NGS) methods for use in the routine clinical microbiological diagnostic laboratory. Eur J Clin Microbiol Infect Dis 38:1059–1070. https://doi.org/10.1007/s10096-019-03520-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bommannan K, Naseem S, Binota J, Varma N, Malhotra P, Varma S (2022) Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: a single center experience. J Postgrad Med 68:93–97. https://doi.org/10.4103/jpgm.JPGM_781_20

Article  CAS  PubMed  Google Scholar 

Branford S, Apperley JF (2022) Measurable residual disease in chronic myeloid leukemia. Haematol 107:2794–2809. https://doi.org/10.3324/haematol.2022.281493

Article  CAS  Google Scholar 

Branford S, Fernandes A, Shahrin N, Maqsood M, Shanmuganathan N, Wadham C (2024) Beyond BCR::ABL1—the role of genomic analyses in the management of CML. J Natl Compr Cancer Netw 22:e237335. https://doi.org/10.6004/jnccn.2023.7335

Article  CAS  Google Scholar 

Braun DA, Burke KP, Van Allen EM (2016) Genomic approaches to understanding response and resistance to immunotherapy. Clin Cancer Res 22:5642–5650. https://doi.org/10.1158/1078-0432.CCR-16-0066

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown AL, Homan C, Drazer MW, Yu K, Lawrence D, Feng J, Arriola-Martinez L, Pozsgai M, McNeely K, Ha T et al (2022) Somatic mutational landscape of hereditary hematopoietic malignancies associated with germline variants in RUNX1, GATA2 and DDX41. Blood 140:4030–4033. https://doi.org/10.1182/blood-2022-167600

Article  Google Scholar 

Cabello-Aguilar S, Vendrell JA, Solassol J (2023) A Bioinformatics toolkit for next-generation sequencing in clinical oncology. CIMB 45:9737–9752. https://doi.org/10.3390/cimb45120608

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho Y-U (2024) The role of next-generation sequencing in hematologic malignancies. Blood Res. 59:11. https://doi.org/10.1007/s44313-024-00010-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chomel J-C, Sorel N, Bonnet M-L, Bertrand A, Brizard F, Roy L, Guilhot F, Turhan AG (2010) Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia. Leuk Lymphoma 51:2103–2111. https://doi.org/10.3109/10428194.2010.520774

Article  CAS  PubMed  Google Scholar 

Cirnu M, Marinescu D-C, Niculae C-F, Negru S-A, Ureche-Fotea A-A, Soare D-S, Bumbea H, Radu E (2024) Quantitative BCR::ABL1 Assay using digital real-time PCR system: clinical applications and insights. DHRHH 2:81–85. https://doi.org/10.59854/dhrrh.2024.2.2.81

Article  Google Scholar 

Crampe M, Andrews C, Fortune A, Langabeer SE (2017) Late emergence of an Imatinib-resistant ABL1 kinase domain mutation in a patient with chronic myeloid leukemia. Case Rep Hematol 2017:1–3. https://doi.org/10.1155/2017/3548936

Article  Google Scholar 

Cross NCP, Ernst T, Branford S, Cayuela J-M, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R et al (2023) European leukemianet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia 37:2150–2167. https://doi.org/10.1038/s41375-023-02048-y

Article  PubMed  PubMed Central  Google Scholar 

Cumbo C, Impera L, Minervini CF, Orsini P, Anelli L, Zagaria A, Coccaro N, Tota G, Minervini A, Casieri P et al (2018) Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for “personalized monitoring” of residual disease in chronic myeloid leukemia patients. Oncotarget 9:10978–10986. https://doi.org/10.18632/oncotarget.23971

Article  PubMed  PubMed Central  Google Scholar 

De Santis S, Monaldi C, Martelli M, Mancini M, Bruno S, Castagnetti F, Gugliotta G, Polakova KM, Ernst T, Maar D et al (2022) CML-184 a novel droplet digital PCR strategy for rapid and sensitive detection of BCR::ABL1 kinase domain mutations conf